The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Demyashkin G.A.

Sechenov First Moscow State Medical University, Moscow, Russia;
Scientific Clinical Center of Russian Railways, Moscow, Russia

Nikitin P.V.

Burdenko Neurosurgery Institute, 4-ya Tverskaya-Yamskaya Str., 16, Moscow, Russia, 125047

IDH1- and IDH2-mutations in brain glial tumors — the new antioncogenic mechanism

Authors:

Demyashkin G.A., Nikitin P.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4): 134‑139

DOI: 10.17116/jnevro201811841134-139

Read: 25746 times

Download PDF (RU)
Contact the author
Table of contents

IDH1- AND IDH2-MUTATIONS IN BRAIN GLIAL TUMORS — THE NEW ANTIONCOGENIC MECHANISM
IDH1- AND IDH2-MUTATIONS IN BRAIN GLIAL TUMORS — THE NEW ANTIONCOGENIC MECHANISM

To cite this article:

Demyashkin GA, Nikitin PV. IDH1- and IDH2-mutations in brain glial tumors — the new antioncogenic mechanism. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4):134‑139. (In Russ.)
https://doi.org/10.17116/jnevro201811841134-139

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118
Machine learning models for brain tumors differential diagnosis. Russian Journal of Preventive Medi­cine. 2025;(9):87-93
TERTp muta­tion screening using digi­tal droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95
Surgery for gliomas of Broca’s area. Burdenko's Journal of Neurosurgery. 2025;(6):38-45
Differential diagnosis of high-grade astrocytic gliomas based on CD44, SOX2, and CIRBP gene expression analysis. Burdenko's Journal of Neurosurgery. 2025;(6-2):14-20
Topic mode­ling of lite­rature in glioma radiomics. Burdenko's Journal of Neurosurgery. 2025;(6-2):57-66
Abstract:

Mutant forms of the gene IDH1 progress significantly slower, have a lower risk of neoplastic transformation, and generally, mutations of this gene have a pronounced anti-oncogenic effect. At the same time, almost all mutations are quite stereotyped (98,9%) and occur in the same region of the gene — R132H mutations. IDH1 gene mutations is a complex multi-layered process, which is a completely new, not previously described anti-oncogene activation mechanism of intracellular protection. The reason that there is a mutation in the tumor cells is associated with de novo blocking differentiation processes and development of brain cells in the development process, as evidenced by severe cerebral hypoplasia in patients with congenital forms of this mutation. A completely new mechanism of antitumor protection has been described — stereotypical IDH1 gene mutation is a gene, in fact, is a key event, causing a cascade of further anti-oncogenic mechanisms in brain gliomas.

Keywords:

IDH1
IDH2
astrocytic gliomas

Authors:

Demyashkin G.A.

Sechenov First Moscow State Medical University, Moscow, Russia;
Scientific Clinical Center of Russian Railways, Moscow, Russia

Nikitin P.V.

Burdenko Neurosurgery Institute, 4-ya Tverskaya-Yamskaya Str., 16, Moscow, Russia, 125047

Close metadata

References:

  1. Gittleman H, Ostrom QT, Rouse CD, Dowling JA, de Blank PM, Kruchko CA, Elder JB, Rosenfeld SS, Seman WR, Sloan AE, Barnholtz-Sloan JS. Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000—2010. Cancer. 2015;1(1):102-112. https://doi.org/10.1093/neuonc/nou253.7
  2. Ostrom QT, Gittleman H, Liao P, Rousse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007—2011. Neuro-Oncol. 2014;(suppl 4):1-63. https://doi.org/10.1093/neuonc/nou223
  3. Ostrom QT, de Blank PM, Kruchko C, Peterson CM, Liao P, Finlay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ, Barnholtz-Sloan JS. CBTRUS statistical Report: Alex’s Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumor Diagnosed in the United States in 2007—2011. Neuro-Oncol. 2015;16 (suppl 10):1-36. https://doi.org/10.1093/neuonc/nou327
  4. Woehrer A, Lau CC, Prayer D, Bauchet L, Rosenfeld M, Capper D, Fisher PG, Kool M, Muller M, Kros JM, Kruchko C, Wiemels J, Wrensch M, Danysh HE, Zouaoui S, Heck JE, Johnson KJ, Qi X, O’Neill BP, Afzal S, Scheurer ME, Bainbridge MN, Nousome D, Bahassiel M, Hainfeller JA, Barnholtz-Sloan JS. Brain Tumor Epidemiology — A Hub within Multidisciplinary Neuro-Oncology. Report on the 15th Brain Tumor Epidemiology Consortium (BTEC) Annual Meeting, Vienna, 2014. Clin Neuropathol. 2015;34(1);40-46. https://doi.org/10.5414/np300846
  5. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015:129:669-678. https://doi.org/10.1007/s00401-015-1405-4
  6. Kshettry VR, Hsieh JK, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Incidence of vestibular schwannomas in the United States. Journal of Neuro-Oncology. 2015;124(2):223-228. https://doi.org/10.1007/s11060-015-1827-9
  7. Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro-Oncology. 2015;17(8):1166-1173. https://doi.org/10.1093/neuonc/nov069
  8. Lym RL, Ostrom QT, Kruchko C, Couce M, Brat DJ, Louis DN, Barnholtz-Sloan JS. Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004—2011. Journal of Neuro-Oncology. 2015;123(1):43-51. https://doi.org/10.1007/s11060-015-1775-4
  9. De Blank PM, Ostrom QT, Rouse C, Wolinsky Y, Kruchko C, Salcido J, Barnholtz-Sloan JS. Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. Cancer Medicine. 2015;4(4):608-619. https://doi.org/10.1002/cam4.410
  10. Rostovtsev DM, Yakovenko IV, Olyushin VE, Vazhenin AV. Epidemiologiya zlokachestvennykh astrotsitom: obzor literatury i sobstvennye dannye. Palliativnaya meditsina i reabilitatsiya. 2014;4:47-54. (In Russ.)
  11. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer. France. 2016.
  12. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131(6):803-820. https://doi.org/10.1007/s00401-016-1545-1
  13. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology. 2015;125(3):503-530. https://doi.org/10.1007/s11060-015-1867-1
  14. Maus A, Peters GJ. Glutamate and α-ketoglutarate: key players in glioma metabolism. Amino Acids. 2016;49(1):21-32. https://doi.org/10.1007/s00726-016-2342-9
  15. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine. 2015;372(26):2481-2498. https://doi.org/10.1056/nejmoa1402121
  16. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129:867-873. https://doi.org/10.1007/s00401-015-1438-8
  17. Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M, Nikiforova MN, Durbin EB, Weiss H, Horbinski C. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neurooncology. 2014;16:1478-1483. https://doi.org/10.1093/neuonc/nou097
  18. Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bahr O, Gielen GH, Simon M. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol. 2015. https://doi.org/10.1007/s00401-015-1495-z
  19. Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol. 2015;39:528-540. https://doi.org/10.1097/pas.0000000000000363
  20. Turkalp Z, Karamchandani L, Jas S. IDHMutation in Glioma. JAMA Neurology. 2014;71(10):1319. https://doi.org/10.1001/jamaneurol.2014.1205
  21. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurgical Focus. 2015;38(3):2. https://doi.org/10.3171/2015.1.focus14745
  22. Iwadate Y, Matsutani T, Hirono S, Ikegami S, Shinozaki N, Saeki N. IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. Journal of Neuro-Oncology. 2015;124(3):493-500. https://doi.org/10.1007/s11060-015-1863-5
  23. Huse JT, Diamond EL, Wang L, Rosenblum MK. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true «oligoastrocytoma»? Acta Neuropathol. 2015;129:151-153. https://doi.org/10.1007/s00401-014-1359-y
  24. Chen N, Yu T, Gong J, Nie L, Chen X, Zhang M, Xu M, Tan J, Su Z, Zhong J, Zhou Q. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients. Pathology. 2016.
  25. Huang LE, Cohen AL, Colman H, Jensen RL, Fults DW, Couldwell WT. IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.13329
  26. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II—III diffuse gliomas. Acta Neuropathol. 2015;29:585-596. https://doi.org/10.1007/s00401-015-1398-z
  27. Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F, Schittenhelm J. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathologica Communications. 2016;4(1). https://doi.org/10.1186/s40478-016-0331-6
  28. Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chi AS. Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. Clinical Cancer Research. 2014;20(11):2898-2909. https://doi.org/10.1158/1078-0432.ccr-13-3052
  29. Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, Deimling A von, Wiestler B. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Scientific Reports. 2015;5(1). https://doi.org/10.1038/srep16238
  30. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an «integrated» diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129:133-146. https://doi.org/10.1007/s00401-014-1370-3
  31. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128:551-559. https://doi.org/10.1007/s00401-014-1326-7
  32. Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128:561-571. https://doi.org/10.1007/s00401-014-1315-x
  33. Sedgwick B, Bates P, Paik J, Jacobs S, Lindahl T. Repair of alkylated DNA: Recent advances. DNA Repair. 2007;6(4):429-442. https://doi.org/10.1016/j.dnarep.2006.10.005
  34. Dango S, Mosammaparast N, Sowa ME, Xiong LJ, Wu F, Park K, Rubin M, Gygi S, Harper JW, Shi Y. DNA unwinding by ASCC3 helicase is coupled to ALKBH3-dependent DNA alkylation repair and cancer cell proliferation. Mol Cell. 2011;44:373-384. https://doi.org/10.1016/j.molcel.2011.08.039
  35. Lee DH, Jin SG, Cai S, Chen Y, Pfeifer GP, O’Connor TR. Repair of methylation damage in DNA and RNA by mammalian AlkB homologues. J Biol Chem. 2005;280:39448-39459. https://doi.org/10.1074/jbc.m509881200
  36. Ringvoll J, Nordstrand LM, Vågbø CB, Talstad V, Reite K, Aas PA, Lauritzen KH, Liabakk NB, Bjørk A, Doughty RW. Repair deficient mice reveal mABH2 as the primary oxidative demethylase for repairing 1meA and 3meC lesions in DNA. The EMBO journal. 2006;25:2189-2198. https://doi.org/10.1038/sj.emboj.7601109
  37. Falnes PØ, Johansen RF, Seeberg E. AlkB-mediated oxidative demethylation reverses DNA damage in Escherichia coli. Nature. 2002;419(6903): 178-182. https://doi.org/10.1038/nature01048
  38. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744. https://doi.org/10.1038/nature08617
  39. Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 2015;13(11):2353-2361. https://doi.org/10.1016/j.celrep.2015.11.029
  40. Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375):2463. https://doi.org/10.1126/scitranslmed.aal2463
  41. Wilcox P, Li CC, Lee M, Shivalingam B, Brennan J, Suter CM, Kaufman K, Lum T, Buckland ME. Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol. 2015;129:147-149. https://doi.org/10.1007/s00401-014-1353-4
  42. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45: 602-612. https://doi.org/10.1038/ng.2611
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.